Privo Technologies Inc., a pioneering biopharmaceutical company known for its innovative approach to drug delivery and cancer treatment, is proud to announce the launch of BeneVet Oncology, a new subsidiary dedicated to improving the health and well-being of companion animals. BeneVet will leverage Privo’s cutting-edge drug delivery technologies to address unmet medical needs in veterinary medicine.

BeneVet aims to revolutionize the way diseases in pets are treated by adapting Privo’s advanced platforms, originally developed for human medicine, to enhance therapeutic options for animals. With a strong focus on safety, efficacy, and ease of administration, BeneVet is poised to transform the landscape of companion animal healthcare.

“Our pets are family members, and they deserve the same level of innovation and care that we dedicate to human health,” said Dr. Manijeh Goldberg, CEO and Founder of Privo Technologies Inc.. “BeneVet will build on Privo’s technological foundation to bring groundbreaking treatments to veterinary medicine, starting with solutions for conditions that currently have limited or inadequate options.”

Innovative Focus Areas

BeneVet’s initial research and development efforts will focus on cutaneous and subcutaneous solid tumors :

• Intratumoral Therapies of Solid Tumors: Leveraging Privo’s PRV131 intratumoral injectable to target tumors in dogs and cats with improved precision and reduced side effects.
• Topical Treatment of Shallow Tumors: Developing sustained-release treatments to provide long-term relief for chronic pain conditions in pets.

A Collaborative Approach

BeneVet will partner with veterinarians, veterinary researchers, and pet owners to ensure that its solutions are both clinically effective and practical in real-world settings. The company will also explore collaborations with animal health organizations to advance veterinary medicine through joint research initiatives.

“By creating BeneVet, we are reaffirming our commitment to innovation and extending it to improve the lives of our beloved companions,” added Dr. Goldberg. “This new chapter is a natural evolution of our mission to make impactful, science-driven advancements accessible to those who need them most.”

About Privo Technologies Inc.

Privo Technologies is a phase 3 clinical-stage biopharmaceutical company committed to improving lives through transformative drug delivery solutions. The company’s proprietary technologies have advanced the treatment of oral cancer and other serious conditions, earning recognition for their innovation and impact on public health. For more information, visit: www.PrivoTechnologies.com

About BeneVet Oncology

BeneVet is a subsidiary of Privo Technologies Inc. focused on advancing the health and well-being of companion animals. By adapting cutting-edge drug delivery systems and collaborating with veterinary professionals, BeneVet aims to deliver safe, effective, and innovative treatments for pets.

For more information, visit: www.Bene-Vet.com

Media Contact

Stefanie Cantin
Privo Technologies Inc.
Email: scantin@Privotechnologies.com